Abstract
Introduction: Uncertainty exists about a possible survival benefit of primary tumor resection (PTR) in synchronous metastatic colon cancer (mCC). Since sidedness of the primary tumor is regarded as an important prognostic factor, our objective was to study the interaction between PTR and sidedness in synchronous mCC. Methods: In this retrospective study, we used data from 2 first-line phase 3 randomized controlled trials (RCTs). A mixed Cox regression model was used to study the multiplicative interaction between PTR and sidedness. We adjusted for age, treatment arm, WHO performance status, number of affected organs by metastases, serum lactate dehydrogenase, and year of enrollment. Results: We found that PTR is associated with better survival in both right-sided (hazard ratio [HR] 0.59 [95% confidence interval 0.42–0.8 2]) and left-sided mCC (HR 0.70 [95% confidence interval 0.52–0.93]). The interaction between PTR and sidedness was not significant (p = 0.45). Conclusion: Our data suggest that the prognostic value of PTR is independent of sidedness. Validation of these results will be performed in ongoing RCTs.
References
1.
’t Lam-Boer
J
, Mol
L
, Verhoef
C
, de Haan
AFJ
, Yilmaz
M
, Punt
CJA
, The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer: a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)
. BMC Cancer
. 2014
;14
(1
):741
.2.
Rahbari
NN
, Lordick
F
, Fink
C
, Bork
U
, Stange
A
, Jäger
D
, Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS: a randomised controlled multicentre trial (ISRCTN30964555)
. BMC Cancer
. 2012
;12
(1
):142
. .3.
Cotte
E
, Villeneuve
L
, Passot
G
, Boschetti
G
, Bin-Dorel
S
, Francois
Y
, GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study
. BMC Cancer
. 2015
;15
(1
):47
. .4.
Nitsche
U
, Stöß
C
, Stecher
L
, Wilhelm
D
, Friess
H
, Ceyhan
GO
. Meta-analysis of outcomes following resection of the primary tumour in patients presenting with metastatic colorectal cancer
. Br J Surg
. 2018
;105
:784
–96
. .5.
van Rooijen
KL
, Shi
Q
, Goey
KKH
, Meyers
J
, Heinemann
V
, Diaz-Rubio
E
, Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: individual patient data analysis of first-line randomised trials from the ARCAD database
. Eur J Cancer
. 2018
;91
(September 2016
):99
–106
. .6.
’t Lam-Boer
J
, Van der Geest
LG
, Verhoef
C
, Elferink
ME
, Koopman
M
, de Wilt
JHW
. Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: a nationwide population-based propensity-score adjusted study in the Netherlands
. Int J Cancer
. 2016
;139
(9
):2082
–94
.7.
Alawadi
Z
, Phatak
UR
, Hu
CY
, Bailey
CE
, You
YN
, Kao
LS
, Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer
. Cancer
. 2017
;123
(7
):1124
–33
. .8.
Kanemitsu
Y
, Shitara
K
, Mizusawa
J
, Hamaguchi
T
, Shida
D
, Komori
K
, Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial
. J Clin Oncol
. 2021
. [Epub ahead of print]. .9.
Holch
JW
, Ricard
I
, Stintzing
S
, Modest
DP
, Heinemann
V
. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials
. Eur J Cancer
. 2017
;70
:87
–98
. .10.
Koopman
M
, Antonini
NF
, Douma
J
, Wals
J
, Honkoop
AH
, Erdkamp
FLG
, Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
. Lancet
. 2007 Jul
;370
(9582
):135
–42
.11.
Tol
J
, Koopman
M
, Cats
A
, Rodenburg
CJ
, Creemers
GJ
, Schrama
JG
, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
. N Engl J Med
. 2009
;360
(6
):563
–72
. .12.
Mekenkamp
LJ
, Koopman
M
, Teerenstra
S
, van Krieken
JH
, Mol
L
, Nagtegaal
ID
, Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases
. Br J Cancer
. 2010
;103
(2
):159
–64
. .13.
Brankovic
M
, Kardys
I
, Steyerberg
EW
, Lemeshow
S
, Markovic
M
, Rizopoulos
D
, Understanding of interaction (subgroup) analysis in clinical trials
. Eur J Clin Invest
. 2019
;49
(8
):e13145
. .14.
Cole
SR
, Hernán
MA
. Adjusted survival curves with inverse probability weights
. Comput Methods Programs Biomed
. 2004
;75
(1
):45
–9
. .15.
Zhang
RX
, Ma
WJ
, Gu
YT
, Zhang
TQ
, Huang
ZM
, Lu
ZH
, Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis
. World J Surg Oncol
. 2017
;15
(1
):138
. .16.
Kim
JH
, Jin
S
, Jeon
MJ
, Jung
HY
, Byun
S
, Jung
K
, Survival benefit of palliative primary tumor resection based on tumor location in patients with metastatic colorectal cancer: a single-center retrospective study
. Korean J Gastroenterol
. 2020
;76
(1
):17
–27
. .17.
Venderbosch
S
, de Wilt
JH
, Teerenstra
S
, Loosveld
OJ
, van Bochove
A
, Sinnige
HA
, Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature
. Ann Surg Oncol
. 2011
;18
(12
):3252
–60
. .18.
Bylsma
LC
, Gillezeau
C
, Garawin
TA
, Kelsh
MA
, Fryzek
JP
, Sangaré
L
, Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: a systematic review and meta-analysis
. Cancer Med
. 2020
;9
(3
):1044
–57
. .19.
Nunes
L
, Aasebø
K
, Mathot
L
, Ljungström
V
, Edqvist
PH
, Sundström
M
, Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis
. Acta Oncol
. 2020
;59
(4
):417
–26
. .20.
Zong
L
, Abe
M
, Ji
J
, Zhu
WG
, Yu
D
. Tracking the correlation between CpG island methylator phenotype and other molecular features and clinicopathological features in human colorectal cancers: a systematic review and meta-analysis
. Clin Transl Gastroenterol
. 2016
;7
:e151
. .21.
Chen
K-H
, Lin
L-I
, Tseng
L-H
, Lin
Y-L
, Liau
J-Y
, Tsai
J-H
, The prognostic role of CpG island methylator phenotype in metastatic colorectal cancer
. J Clin Oncol
. 2018 Feb 1
;36
(4 Suppl
):667
. .22.
Stintzing
S
, Wirapati
P
, Lenz
HJ
, Neureiter
D
, Fischer von Weikersthal
L
, Decker
T
, Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
. Ann Oncol
. 2019
;30
(11
):1796
–803
. .23.
Guinney
J
, Dienstmann
R
, Wang
X
, de Reyniès
A
, Schlicker
A
, Soneson
C
, The consensus molecular subtypes of colorectal cancer
. Nat Med
. 2015
;21
(11
):1350
–6
. .24.
Hugen
N
, Van de Velde
CJH
, De Wilt
JHW
, Nagtegaal
ID
. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype
. Ann Oncol
. 2014
;25
(3
):651
–7
. .25.
Brouwer
NPM
, van der Kruijssen
DEW
, Hugen
N
, de Hingh
IHJT
, Nagtegaal
ID
, Verhoeven
RHA
, The impact of primary tumor location in synchronous metastatic colorectal cancer: differences in metastatic sites and survival
. Ann Surg Oncol
. 2020
;27
(5
):1580
–8
. .26.
Flemer
B
, Lynch
DB
, Brown
JM
, Jeffery
IB
, Ryan
FJ
, Claesson
MJ
, Tumour-associated and non-tumour-associated microbiota in colorectal cancer
. Gut
. 2017
;66
(4
):633
–43
. .27.
Dejea
CM
, Wick
EC
, Hechenbleikner
EM
, White
JR
, Mark Welch
JL
, Rossetti
BJ
, Microbiota organization is a distinct feature of proximal colorectal cancers
. Proc Natl Acad Sci U S A
. 2014
;111
(51
):18321
–6
. .28.
Stintzing
S
, Tejpar
S
, Gibbs
P
, Thiebach
L
, Lenz
HJ
. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
. Eur J Cancer
. 2017
;84
:69
–80
. .29.
Poultsides
GA
, Paty
PB
. Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective
. Ther Adv Med Oncol
. 2011
;3
(1
):35
–42
. .30.
Xu
H
, Xia
Z
, Jia
X
, Chen
K
, Li
D
, Dai
Y
, Primary tumor resection is associated with improved survival in stage IV colorectal cancer: an instrumental variable analysis
. Sci Rep
. 2015
;5
(August
):16516
. .31.
Kakarala
M
, Wicha
MS
. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy
. J Clin Oncol
. 2008
;26
(17
):2813
–20
. .32.
Kim
MY
, Oskarsson
T
, Acharyya
S
, Nguyen
DX
, Zhang
XH
, Norton
L
, Tumor self-seeding by circulating cancer cells
. Cell
. 2010
;139
(7
):1315
–26
. .33.
Turner
N
, Tran
B
, Tran
PV
, Sinnathamby
M
, Wong
HL
, Jones
I
, Primary tumor resection in patients with metastatic colorectal cancer is associated with reversal of systemic inflammation and improved survival
. Clin Colorectal Cancer
. 2015
;14
(3
):185
–91
. .34.
Dorajoo
SR
, Tan
WJ
, Koo
SX
, Tan
WS
, Chew
MH
, Tang
CL
, A scoring model for predicting survival following primary tumour resection in stage IV colorectal cancer patients with unresectable metastasis
. Int J Colorectal Dis
. 2015
;31
:235
–45
. .35.
Li
ZM
, Peng
YF
, Du
CZ
, Gu
J
. Colon cancer with unresectable synchronous metastases: the AAAP scoring system for predicting the outcome after primary tumour resection
. Colorectal Dis
. 2016
;18
(3
):255
–63
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
